A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Herpes simplex virus DNA vaccine (Primary)
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Sponsors Vical
  • Most Recent Events

    • 11 Jun 2018 According to the Vical media release, company will continue to follow the active patients until July 2018.
    • 11 Jun 2018 Status changed from active, no longer recruiting to discontinued, according to the Vical media release.
    • 11 Jun 2018 Primary endpoint lesion recurrences has not been met, according to a Vical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top